Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact... IntroductionBiosimilars are biological medicines that are highly similar to the originator product. Availability of biosimilars for biological products which go off patent is expected to decrease per‐patient treatment costs and provide greater patient access, contributing to the reduction in disability, morbidity and mortality associated with inflammatory diseases.There are well‐defined regulatory guidelines in the United States (US) and the European Union (EU) on scientific considerations for demonstration of biosimilarity; the EU guidelines are considered the gold standard for authorization of biosimilar medicines. From the perspective of interchangeability between an originator and a biosimilar, the US Food and Drug Administration (US FDA) has recently issued a draft guidance on considerations in demonstrating interchangeability of a biosimilar with a reference product (originator). In the EU, there is no separate designation of interchangeability, rather biosimilars can be viewed as interchangeable, and the decision is left to individual member states for framing the rules. Apart from the regulatory perspective, the evaluation of the effect of multiple switches between originator and biosimilar with regard to efficacy, safety and immunogenicity is of great interest to physicians and patients.GP2015 (Erelzi™) is an etanercept biosimilar approved by the US FDA for treatment of rheumatoid arthritis and polyarticular juvenile http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study

Loading next page...
 
/lp/wiley/multiple-switches-between-gp2015-an-etanercept-biosimilar-with-8D0cL5fac4
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
D.O.I.
10.1111/jdv.14605
Publisher site
See Article on Publisher Site

Abstract

IntroductionBiosimilars are biological medicines that are highly similar to the originator product. Availability of biosimilars for biological products which go off patent is expected to decrease per‐patient treatment costs and provide greater patient access, contributing to the reduction in disability, morbidity and mortality associated with inflammatory diseases.There are well‐defined regulatory guidelines in the United States (US) and the European Union (EU) on scientific considerations for demonstration of biosimilarity; the EU guidelines are considered the gold standard for authorization of biosimilar medicines. From the perspective of interchangeability between an originator and a biosimilar, the US Food and Drug Administration (US FDA) has recently issued a draft guidance on considerations in demonstrating interchangeability of a biosimilar with a reference product (originator). In the EU, there is no separate designation of interchangeability, rather biosimilars can be viewed as interchangeable, and the decision is left to individual member states for framing the rules. Apart from the regulatory perspective, the evaluation of the effect of multiple switches between originator and biosimilar with regard to efficacy, safety and immunogenicity is of great interest to physicians and patients.GP2015 (Erelzi™) is an etanercept biosimilar approved by the US FDA for treatment of rheumatoid arthritis and polyarticular juvenile

Journal

Journal of the European Academy of Dermatology & VenereologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Access to DeepDyve database
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off